Serum cholestasis markers as predictors of early outcome after liver transplantation

Clinical Transplantation

Volumn 18, Issue 2, 2004, Pages 130-136

  Ben Ari, Ziv ^a   Weiss Schmilovitz, Hemda ^a   Sulkes, Jaqueline ^a   Brown, Marius ^a   Bar Nathan, Nathan ^a   Shaharabani, Ezra ^a   Yussim, Alexander ^a   Shapira, Zaki ^a   Tur Kaspa, Ran ^a   Mor, Eytan ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

Cholestasis; Liver transplantation; Outcome; Predictor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; AMPICILLIN; AZATHIOPRINE; BILIRUBIN; BIOLOGICAL MARKER; CEFOTAXIME; CORTICOSTEROID; CYCLOSPORIN; GAMMA GLUTAMYLTRANSFERASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; STEROID; SULFAMETHOXAZOLE; TACROLIMUS; TRIMETHOPRIM; URSODEOXYCHOLIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CHOLESTASIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE ASSOCIATION; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GRAFT REJECTION; HEALTH CARE FACILITY; HIGH RISK PATIENT; HUMAN; INTERNATIONAL STANDARD UNIT; ISRAEL; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORBIDITY; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEPSIS; STATISTICAL ANALYSIS; STUDENT T TEST; SURGICAL MORTALITY; TREATMENT OUTCOME;

ALKALINE PHOSPHATASE; BILIRUBIN; BIOLOGICAL MARKERS; CHOLESTASIS; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; INTERNATIONAL NORMALIZED RATIO; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; SEPSIS; SERUM ALBUMIN; SURVIVAL RATE;

EID: 12144287656     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1399-0012.2003.00135.x     Document Type: Article

References (32)

1. Bismuth H, Castaing D, Ericzon BG et al. Hepatic transplantation in Europe. Lancet 1987: 2: 674.
2. First MR. Transplantation in the nineties. Transplantation 1992: 53: 1.
3. Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation. N Engl J Med 1989: 321: 1092.
4. Belle SH, Beringer KC, Detre KM. An update on liver transplantation in the United States: Recipients characteristics and outcome. In: Cecka JM, Terrasaki PI eds. Clinical Transplants 1995. Los Angeles: UCLA Tissue Typing Laboratory, 1996: 15.
5. Baliga P, Merion RM, Turcotte JE et al. Preoperative risk factor assessment in liver transplantation. Surgery 1992: 112: 704.
6. Shaw BW, Wood RP, Gordon RD, Iwatsuki S, Gillquist WP, Starzl TE. Influence of selected patient variables and operative blood loss on six-month survival following liver transplantation. Semin Liver Dis 1985: 5: 385.
7. Cuervas-Mons V, Millan I, Gavaler JS, Starzl TE, van Thiel DH. Prognostic value of preoperatively obtained clinical and laboratory data in predicting survival following orthotopic liver transplantation. Hepatology 1986: 6: 922.
8. Doyle HR, Marino IR, Jabbour N et al. Early death or retransplantation in adults after orthotopic liver transplantation. Can outcome be predicted? Transplantation 1994: 57: 1028.
9. Markmann JF, Markmann JW, Markmann DA et al. Preoperative factors associated with outcome and their impact on resource use in 1148 consecutive primary liver transplants. Transplantation 2001: 72: 1113.
10. Heneghan MA, Sylvestre PB. Cholestatic diseases of liver transplantation. Semin Gastrointest Dis 2001: 12: 133.
11. Ploeg RJ, D'Alessandro AM, Knechtle SJ et al. Risk factors for primary dysfunction after liver transplantation: A multivariate analysis. Transplantation 1993: 55: 807.
12. Deschenes M, Belle SH, Krom RAF, Zetterman RK, Lake JR. Early allograft dysfunction after liver transplantation. A definition and predictors of outcome. Transplantation 1998: 66: 302.
13. Cutrin JC, Cantino D, Biasi F et al. Reperfusion damage to the bile canaliculi in transplanted human liver. Hepatology 1996: 24: 1053.
14. Starzl TE, Iwatsuki S, Esquivel CO et al. Refinements in the surgical technique of liver transplantation. Semin Liver Dis 1985: 5: 349.
15. Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the donor liver: Risk factors for poor function after orthotopic liver transplantation. Hepatology 1994: 20: 829.
16. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992: 20: 864.
17. Mor E, Klintmalm GB, Gonwa TA et al. The use of marginal donors for liver transplantation. A retrospective study of 365 liver donors. Transplantation 1992: 53: 383.
18. Edwards EB, Roberts JB, McBride MA, Schulak JA, Hunsickler LG. The effect of the volume of procedures at transplantation centers on mortality after liver transplantation. N Engl J Med 1999: 341: 2049.
19. Moseley RH, Wang W, Takeda H et al. Effects of endotoxin on bile acid transport in rat liver: A potential model for sepsis-associated cholestasis. Am J Physiol 1996: 271: G137.
20. Perkins JD, Rakela J, Sterio S, Banks PM, Wiesner RH, Krom RA. Immunohistologic pattern of the portal T-lymphocyte infiltration in hepatic allograft rejection. Mayo Clin Proc 1989: 64: 565.
21. Angermuller S, Steinmetz I, Weber T, Czerny F, Hanisch E. Kusterer K. Significant increase of Kupffer cells associated with loss of Na +, K +-ATPase activity in rat hepatic allograft rejection. Transplantation 1997: 63: 1562.
22. Mutimer D. CMV infection after liver transplantation. J Hepatol 1996: 25: 259.
23. Stratta RJ, Shaefer MS, Markin RS et al. Clinical patterns of cytomegalovirus disease after liver transplantation. Arch Surg 1989: 124: 1443.
24. Laupacis A, Keown PA, Ulan RA, Sinclair NR, Stiller CR. Hyperbilirubinemia and cyclosporine level. Lancet 1981: 2: 1426.
25. Kadmon M, Klunemann C, Bohme M et al. Inhibition by cyclosporine A of adenosine triphosphate-dependent transport from the hepatocyte into bile. Gastroenterology 1993: 104: 1507.
26. Bloomer JR, Berk PD, Howe RB, Berlin N. Interpretation of plasma bilirubin levels based on studies of radioactive bilirubin. JAMA 1971: 218: 216.
27. Moia M, Martinelli I, Gridelli B, Langer M, Galmarini D, Mannucci PM. Prognostic value of hemostatic parameters after liver transplantation. J Hepatol 1992: 15: 125.
28. George DL, Arnow PM, Fox AS et al. Bacterial infection as a complication of liver transplantation: Epidemiology and risk factors. Rev Infect Dis 1991: 13: 387.
29. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Predicting bacteremia and bacteremic mortality in liver transplant recipients. Liver Transpl 2000: 6: 54.
30. Poupon R, Poupon RE. Ursodeoxycholic acid therapy for chronic cholestatic conditions in adults and children. Pharmacol Ther 1995: 66: 1.
31. Soderdahl G, Nowak G, Duraj F, Wang FH, Einarsson C, Ericzon BG. Ursodeoxycholic acid increased bile flow and affects bile composition in the early postoperative phase following liver transplantation. Transpl Int 1998: 11: S231.
32. Barne D, Talenti D, Cammell G et al. A randomized clinical trial of ursodeoxycholic acid as adjuvant treatment to prevent liver transplant rejection. Hepatology 1997: 26: 853.